ACE and heart failure: One important area for further investigation is the need for larger, more diverse trials that explore the long-term efficacy and safety of beta-blockers and ACE inhibitors across broader heart failure populations, particularly in those with preserved ejection fraction, as the majority of current data is focused on reduced ejection fraction [24].